A new prescription for growth? Statins, cholesterol and cartilage homeostasis
- 1 April 2015
- journal article
- editorial
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 23 (4) , 503-506
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research (2539)
This publication has 28 references indexed in Scilit:
- Statin treatment rescues FGFR3 skeletal dysplasia phenotypesNature, 2014
- Control of chondrocyte gene expression by actin dynamics: a novel role of cholesterol/Ror-α signalling in endochondral bone growthJournal of Cellular and Molecular Medicine, 2010
- Role of Cholesterol in the Regulation of Growth Plate Chondrogenesis and Longitudinal Bone GrowthJournal of Biological Chemistry, 2004
- Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathwayNature Medicine, 2003
- A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3Proceedings of the National Academy of Sciences, 1999
- Fibroblast Growth Factor Receptor 3 Is a Negative Regulator of Bone GrowthCell, 1996
- Stop codon FGFR3 mutations in thanatophoric dwarfism type 1Nature Genetics, 1995
- Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3Nature Genetics, 1995
- Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasiaNature, 1994
- Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasiaCell, 1994